Dr Amanda Francisco

Senior Research Fellow

Amanda.Francisco [at] lshtm.ac.uk

Dr Francisco's obtained a BSc in Nutrition and an MSc and PhD in Biological Sciences, both from the Federal University of Ouro Preto in Brazil. In 2012, she was awarded a scholarship from The Brazilian National Council for Scientific and Technological Development to work on the Trypanosoma cruzi heart pathology in John Kelly' lab at LSHTM where she undertook this post-doctoral work for 2 years. In 2014, Amanda started to work at LSHTM funded by Drugs for Neglected Diseases initiative (DNDi). DNDi is a non-profit research and development organization that is developing new treatments for neglected diseases. Currently, Amanda is working with drug discovery for DNDi, GSK, Novartis and others using the bioluminescence in vivo image system for T. cruzi and on the pathogenesis of Chronic Chagasic Cardiomyopathy (CCC).

Projects

Exploit in vivo imaging technology to study disease pathogenesis and assess drug effectiveness.

Publications

23 May 2019

A single dose of antibody-drug conjugate cures a stage 1 model of African trypanosomiasis

PLoS Negl Trop Dis

Peer-reviewed article

31 Oct 2017

Genome-wide mutagenesis and multi-drug resistance in American trypanosomes induced by the front-line drug benznidazole.

Scientific Reports

Peer-reviewed article

14 Sep 2017

Discovery and Optimization of 5-Amino-1,2,3-triazole-4-carboxamide Series against Trypanosoma cruzi

Journal of Medicinal Chemistry

Peer-reviewed article

23 Aug 2017

Biological factors that impinge on Chagas disease drug development.

Parasitology

Peer-reviewed article

17 Oct 2016

Nitroheterocyclic drugs cure experimental Trypanosoma cruzi infections more effectively in the chronic stage than in the acute stage

Scientific Report

Peer-reviewed article

16 Oct 2016

Host and parasite genetics shape a link between Trypanosoma cruzi infection dynamics and chronic cardiomyopathy

Cell Microbiology

Peer-reviewed article

23 Jul 2016

Insertion of Isocyanides into N-Si Bonds: Multicomponent Reactions with Azines Leading to Potent Antiparasitic Compounds

Angew Chem Int Ed Eng

Peer-reviewed article

01 Aug 2015

Limited Ability of Posaconazole To Cure both Acute and Chronic Trypanosoma cruzi Infections Revealed by Highly Sensitive In Vivo Imaging

Antimicrob Agents Chemother

Peer-reviewed article

16 Sep 2014

Bioluminescence imaging of chronic Trypanosoma cruzi infections reveals tissue-specific parasite dynamics and heart disease in the absence of locally persistent infection

Cell Microbiology

Peer-reviewed article

LCNTDR

Search

Dr Amanda Francisco

Projects

Publications

A single dose of antibody-drug conjugate cures a stage 1 model of African trypanosomiasis

Genome-wide mutagenesis and multi-drug resistance in American trypanosomes induced by the front-line drug benznidazole.

Discovery and Optimization of 5-Amino-1,2,3-triazole-4-carboxamide Series against Trypanosoma cruzi

Biological factors that impinge on Chagas disease drug development.

Nitroheterocyclic drugs cure experimental Trypanosoma cruzi infections more effectively in the chronic stage than in the acute stage

Host and parasite genetics shape a link between Trypanosoma cruzi infection dynamics and chronic cardiomyopathy

Insertion of Isocyanides into N-Si Bonds: Multicomponent Reactions with Azines Leading to Potent Antiparasitic Compounds

Limited Ability of Posaconazole To Cure both Acute and Chronic Trypanosoma cruzi Infections Revealed by Highly Sensitive In Vivo Imaging

Bioluminescence imaging of chronic Trypanosoma cruzi infections reveals tissue-specific parasite dynamics and heart disease in the absence of locally persistent infection

Contact us